Swiss Life Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.2M | Buy |
190,154
+30,873
| +19% | +$2.59M | 0.07% | 200 |
|
|
2026
Q1 | $12.8M | Buy |
159,281
+8,949
| +6% | +$738K | 0.06% | 236 |
|
|
2025
Q4 | $12.8M | Sell |
150,332
-2,944
| -2% | -$242K | 0.07% | 223 |
|
|
2025
Q3 | $11.9M | Buy |
153,276
+4,336
| +3% | +$339K | 0.06% | 238 |
|
|
2025
Q2 | $11.6M | Sell |
148,940
-40,571
| -21% | -$3.03M | 0.07% | 216 |
|
|
2025
Q1 | $13.7M | Buy |
189,511
+53,575
| +39% | +$3.83M | 0.1% | 162 |
|
|
2024
Q4 | $10.1M | Buy |
135,936
+45,576
| +50% | +$3.19M | 0.07% | 195 |
|
|
2024
Q3 | $5.96M | Buy |
90,360
+27,165
| +43% | +$1.97M | 0.07% | 240 |
|
|
2024
Q2 | $5.84M | Buy |
63,195
+7,742
| +14% | +$686K | 0.07% | 231 |
|
|
2024
Q1 | $5.3M | Sell |
55,453
-76,024
| -58% | -$6.39M | 0.07% | 223 |
|
|
2023
Q4 | $10M | Buy |
131,477
+25,791
| +24% | +$1.79M | 0.12% | 195 |
|
|
2023
Q3 | $7.32M | Sell |
105,686
-38,264
| -27% | -$3.07M | 0.11% | 213 |
|
|
2023
Q2 | $13.6M | Sell |
143,950
-34,622
| -19% | -$3.01M | 0.2% | 120 |
|
|
2023
Q1 | $14.8M | Buy |
178,572
+87,299
| +96% | +$6.86M | 0.22% | 106 |
|
|
2022
Q4 | $6.82M | Sell |
91,273
-4,556
| -5% | -$351K | 0.11% | 220 |
|
|
2022
Q3 | $7.92M | Sell |
95,829
-7,470
| -7% | -$719K | 0.14% | 184 |
|
|
2022
Q2 | $9.84M | Buy |
103,299
+8,793
| +9% | +$910K | 0.16% | 161 |
|
|
2022
Q1 | $11.1M | Sell |
94,506
-3,068
| -3% | -$344K | 0.16% | 145 |
|
|
2021
Q4 | $12.6M | Sell |
97,574
-3,273
| -3% | -$382K | 0.16% | 143 |
|
|
2021
Q3 | $11.4M | Buy |
100,847
+12,362
| +14% | +$1.41M | 0.16% | 154 |
|
|
2021
Q2 | $7.78M | Buy |
88,485
+6,525
| +8% | +$615K | 0.08% | 240 |
|
|
2021
Q1 | $6.86M | Buy |
81,960
+1,441
| +2% | +$122K | 0.1% | 243 |
|
|
2020
Q4 | $7.35M | Buy |
80,519
+71,675
| +810% | +$5.95M | 0.11% | 222 |
|
|
2020
Q3 | $706K | Sell |
8,844
-3,431
| -28% | -$268K | 0.01% | 392 |
|
|
2020
Q2 | $849K | Buy |
12,275
+785
| +7% | +$55.8K | 0.01% | 382 |
|
|
2020
Q1 | $722K | Sell |
11,490
-40,209
| -78% | -$2.9M | 0.01% | 393 |
|
|
2019
Q4 | $4.02M | Buy |
51,699
+8,148
| +19% | +$636K | 0.08% | 206 |
|
|
2019
Q3 | $3.19M | Buy |
43,551
+37,599
| +632% | +$2.64M | 0.04% | 243 |
|
|
2019
Q2 | $366K | Buy |
5,952
+711
| +14% | +$43K | ﹤0.01% | 493 |
|
|
2019
Q1 | $334K | Buy |
+5,241
| New | +$299K | ﹤0.01% | 455 |
|
|
2018
Q4 | – | Sell |
-7,977
| Closed | -$463K | – | 284 |
|
|
2018
Q3 | $463K | Buy |
7,977
+2,184
| +38% | +$107K | 0.01% | 455 |
|
|
2018
Q2 | $281K | Sell |
5,793
-11,958
| -67% | -$558K | ﹤0.01% | 488 |
|
|
2018
Q1 | $826K | Buy |
17,751
+11,958
| +206% | +$519K | 0.01% | 386 |
|
|
2017
Q4 | $218K | Buy |
+5,793
| New | +$213K | ﹤0.01% | 470 |
|
|
2016
Q2 | – | Sell |
-17,826
| Closed | -$524K | – | 330 |
|
|
2016
Q1 | $524K | Sell |
17,826
-19,902
| -53% | -$549K | 0.02% | 265 |
|
|
2015
Q4 | $993K | Sell |
37,728
-16,608
| -31% | -$431K | 0.04% | 157 |
|
|
2015
Q3 | $1.29M | Buy |
54,336
+39,804
| +274% | +$961K | 0.06% | 126 |
|
|
2015
Q2 | $345K | Sell |
14,532
-6,126
| -30% | -$138K | 0.01% | 230 |
|
|
2015
Q1 | $490K | Buy |
+20,658
| New | +$463K | 0.02% | 183 |
|
Other funds holding EW
Swiss Life Asset Management's EW Position: Q2 2026 in Review
Swiss Life Asset Management increased its Edwards Lifesciences (EW) stake by 19% in Q2 2026, buying an estimated $2.59M and bringing the position to 190,154 shares worth $17.2M. The position accounts for 0.07% of the portfolio, ranked #200.
Swiss Life Asset Management first reported a position in EW in Q1 2015 and has held it in 39 quarters since. 1,050 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Swiss Life Asset Management held 190,154 shares of Edwards Lifesciences worth $17.2M as of Q2 2026.
- Swiss Life Asset Management bought 30,873 Edwards Lifesciences shares in Q2 2026, an estimated $2.59M.
- Edwards Lifesciences made up 0.07% of Swiss Life Asset Management's portfolio in Q2 2026, its #200 holding.
- Swiss Life Asset Management first reported a position in Edwards Lifesciences in Q1 2015 and has held it in 39 quarters since.
- 1,050 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.